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Abstract
Purpose: NK1 receptors have been implicated in various neuropsychiatric and other disorders. R116301 is a
selective NK1 receptor antagonist. In this pilot study, [11C]R116301 was evaluated as a potential positron emission
tomography (PET) ligand for the NK1 receptor.
Procedures: Two dynamic PET studies were performed in three normal volunteers before and after a blocking dose
of aprepitant. Data were analyzed using striatum to cerebellum standardized uptake value (SUV) ratios.
Results: Baseline SUV ratios at 60–90 min after injection ranged from 1.22 to 1.70. Following aprepitant
administration, this specific signal was completely blocked. Aprepitant administration did not significantly affect
uptake in cerebellum, confirming the absence of NK1 receptors in cerebellum.
Conclusion: These preliminary results indicate that [11C]R116301 has potential as a radioligand for in vivo
assessment of NK1 receptors in the human brain.
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Introduction
Tachykinins are a class of neuropeptides that are involvedin a variety of biological functions in the central and
peripheral nervous systems [1–3]. Tachykinin receptors have
been divided into three subtypes according to their preferred
ligands: neurokinin 1 (NK1), NK2, and NK3. NK1
receptors, for which substance P has the highest affinity,
have been of particular interest because of their potential
implication in various neuro-psychiatric and other disorders.
Autoradiography studies of the brain of various species have
demonstrated the presence of NK1 receptors in several
cerebral structures with the highest density in striatum [4]
and negligible density in cerebellum [5]. NK1 antagonists
could potentially be used for treating a variety of disorders
[6–8]. Originally, selective nonpeptide antagonists of the
NK1 receptor were studied as potential analgesic compounds
[9]. Several studies have provided evidence that NK1
receptor antagonists might be effective in the treatment of
anxiety disorders and depression [10–13], although a recent
clinical study in depression could not confirm these findings
[14]. The highly selective NK1 antagonist aprepitant [14],
5-[[(2R,3S]-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]eth-
oxy]-3-(4-fluorphenyl)-4-morpholinyl]methyl]-1,2-dihydro-
3H-1,2,4-triazol-3-one, however, is effective in the treatment
of nausea and emesis after chemotherapy and is already in
routine clinical use as an anti-emetic agent [15, 16]. To
assess novel drugs targeting the NK1 receptor, development
of a positron emission tomography (PET) tracer for this
target is warranted, as this would provide a unique in vivo
means of measuring receptor occupancy. In addition, in vivo
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imaging studies might provide new possibilities for studying
the role of the NK1 receptor in neuro-psychiatric disorders.
Although several NK1 agonists and antagonists have
been labeled successfully for in vitro use, to date, most
attempts to develop tracers for in vivo imaging studies have
not been successful [17–19]. For example, although the
radioiodinated selective NK1 antagonist L-703606 was
useful for labeling NK1 receptors in vitro [20], it failed to
provide a specific signal in vivo in rat and monkey [21]. For
the high affinity antagonist [11C]GR205171, promising
results were obtained in monkeys [22], providing images
that reflected specific binding to NK1 receptors. Its use was
limited, however, by the fact that it did not reach equilibrium
within 90 min, which is close to the maximum scanning time
possible with a carbon-11 labeled ligand. Recently, [2-[18F]
fluoromethoxy-5-(5-trifluoromethyltetrazol-1-yl)benzyl]-
([2S,3S]-2-phenylpiperidin-3-yl)-amine ([18F]SPARQ) was
developed as a fluorine-18 labeled alternative. SPARQ is
structurally related to GR205171 and is a selective high-
affinity antagonist of the NK1 receptor [4, 21, 23].
Unfortunately, in areas with high receptor densities, [18F]
SPARQ only reached equilibrium after 6 h, limiting its use
for clinical or intervention studies [5]. In addition, plasma
kinetics of [18F]SPARQ were fast, and 90 min after
injection, the amount of parent compound in blood was too
low to be measured reliably [5]. As such, at present there is
no “ideal” tracer for human NK1 receptors and, therefore,
alternative compounds need to be investigated.
N1-(2,6-Dimethylphenyl)-2-(4-{(2R,4S)-2-benzyl-1-[3,5-
i(trifluoromethyl) benzoyl]hexahydro-4-pyridinyl}pipera-
zino)acetamide (R116301) is an orally active, potent, and
selective nonpeptide NK1 receptor antagonist with a Ki of
0.45 nM against human NK1 receptors [24]. The affinity for
human NK2 and NK3 receptors is 1,600- and 230-fold
lower, respectively. At high concentrations, R116301 inter-
acts with rat Na+ and Ca2+ ion channel binding sites (Ki9
2 μM), but it does not interact with other receptors, ion
channels, or transporter sites at a concentration of 10 μM.
R116301 suppresses various aspects of substance P induced
behavior in vivo and behaves as a full antagonist in vitro
[25]. Recently, R116301 was labeled with carbon-11 [24].
The present study is the first application of [11C]R116301
in humans. The aim of the study was to evaluate presence




Three healthy subjects, two men aged 46 and 42 and one woman aged 25,
were included. Subjects were studied within 21 days after eligibility
screening, which consisted of medical history including Structured Clinical
Interview for DSM-IV Axis I disorders [26], history of alcohol and drug
abuse, physical examination, vital signs and electrocardiogram, laboratory
(blood and urine) assessments, and extensive drugs (of abuse) screening.
The female subject was practicing an effective method of birth control, and
pregnancy tests were performed at screening and on the day of the study.
Volunteers were medication-free for at least 14 days prior to PET scanning.
In addition, subjects underwent a structural magnetic resonance imaging
(MRI) scan within 14 days prior to the actual PET study to exclude any
clinically significant abnormalities and for coregistration with the PET
images. The study was approved by the Medical Ethics Committee of the
VU University Medical Centre. Subjects gave written informed consent
prior to entering the study.
Fig. 1. a [11C]R116301 SUV images (60–90 min post
injection) for subject number 1, before (left) and 3.5 h after
(right) oral administration of 125 mg aprepitant. b Pre- and
post-aprepitant SUV curves for striatum and cerebellum of
subject 1. c Pre-aprepitant striatum to cerebellum SUVr.
Note that SUV is normalized to body surface area and that
results are expressed as milliSUV (mSUV).
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Scanning Protocol
Each PET session consisted of two [11C]R116301 scans on the same day,
separated by 5 h. [11C]R116301 was synthesized as described previously
[24]. The first scan was under baseline conditions, while the second was
performed 3.5 h after a single oral dose of 125 mg of the NK1 antagonist
aprepitant (EMEND®). Pretreatment with 125 mg aprepitant is expected
to nearly block specific uptake of [11C]R116301, as it has been reported
that this dose leads to an occupancy of NK1 receptors of more than 90%
[4].
PET scans were acquired using an ECAT EXACT HR+ PET scanner
(Siemens/CTI, Knoxville, TN, USA) [27]. All subjects received an
indwelling radial artery cannula for arterial sampling. After a 10 min 2D
transmission scan, used to correct the subsequent emission scan for tissue
attenuation, a 3D dynamic [11C]R116301 scan was performed. This scan
consisted of 23 frames with progressive increase in frame duration (1×
15, 3×5, 3×10, 2×30, 3×60, 2×150, 2×300, and 7×600 s), resulting in
a total scan duration of 90 min. The mean (±SD) [11C]R116301 tracer
dose, administered using an injector (Multilevel CT Injector; Medrad,
Pittsburgh, PA, USA), was 427±44 MBq, with a specific activity of 31±
7 GBq/μmol.
During the [11C]R116301 scan, arterial blood was monitored continu-
ously using an on-line detection system (Veenstra Insruments, Joure,
Netherlands) [28]. In addition, at set times manual blood samples were
collected for measurement of metabolite fractions.
Magnetic resonance imaging was performed using a 1.5-T Sonata
system (Siemens, Erlangen, Germany) with a standard receiver head coil.
For each subject, a coronal 3D gradient-echo T1-weighted sequence (matrix
256×160; inversion time, 300 ms; TR=15 ms; TE=7 ms; flip angle=80;
voxel size 1×1×1.5 mm; 160 sections) was acquired.
Image Analysis
[11C]R116301 scans were reconstructed using a FORE + 2D filtered back
projection algorithm [29] and a Hanning filter with a cut-off at 0.5 times the
Nyquist frequency, including usual corrections for decay, dead time,
attenuation, scatter, and randoms. A zoom factor of 2 and an image matrix
size of 256×256 were used, resulting in a final image resolution of ~7 mm
full width at half maximum and a voxel size of 1.2×1.2×2.4 mm3.
Baseline and post-aprepitant dynamic PET scans were coregistered to
each other and subsequently to individual MRI scans using the software
package MIRIT [30, 31]. Using anatomical criteria and the three-
dimensional software program DISPLAY (http://www.bic.mni.mcgill.ca/
software/Display), regions of interest (ROIs) were defined manually on the
individual MRI scan for the following structures: caudate, putamen, medial
temporal lobe (MTL), thalamus, cingulate, frontal cortex, parietal cortex,
insular cortex, occipital cortex, and cerebellum. MRI scans were segmented
into grey and white matter and, except for cerebellum, only grey matter
voxels within a ROI were used for further analysis [32]. As segmentation in
the cerebellum is less accurate, all voxels within the cerebellum ROI were
used. Finally, tissue time–activity curves were generated by projecting these
ROIs onto all dynamic frames.
Assessment of Specific Signal
During the study, significant sticking of [11C]R116301 to the wall of the
polytetrafluorethylene tubing was suspected, as flushing the line did not
result in a reduction of detector counts. This was confirmed in a
retrospective experiment, where significant residual activity was measured
after rinsing a tube that had been filled with [11C]R116301 containing
blood. Due to this sticking, arterial input curves were unreliable, making
compartmental analysis impossible. Therefore, for this first analysis,
standardized uptake values (SUV) were used. SUV represents the mean
(over a time interval) tissue concentration, normalized for injected dose and
either subject weight, lean body mass, or body surface area [33]. SUV were
obtained for all ROIs of both baseline and post-aprepitant [11C]R116301
scans. As it is known that the level of NK1 receptors is negligible in
cerebellum [5], the target to cerebellum SUV ratio (SUVr) was used for
estimating the size of the specific signal, and this ratio was also used as
outcome parameter for assessing the effects of aprepitant. Emphasis was on
striatum, as this structure has the greatest density of NK1 receptors.
Results
Plasma clearance of [11C]R116301 was rapid with no
differences between pre- and post-aprepitant scans (data
not shown). Due to this rapid plasma clearance, metabolites
could not be measured after 60 min. Metabolite fractions
(determined using the manual samples) at 40 min post
injection ranged from 20% to 45% (average 35%).
As expected, highest uptake was observed in striatum,
with intermediate uptake in cortical areas, and lowest uptake
in white matter and cerebellum. In Fig. 1a, pre- and post-
aprepitant SUV images (60–90 min post injection) are
shown for one of the subjects (subject 1), illustrating
substantial reduction of [11C]R116301 uptake after aprepi-
tant administration. In contrast to striatum, aprepitant
administration did not significantly affect [11C]R116301
SUV in cerebellum, confirming absence of NK1 receptors in
cerebellum (Fig. 1b).
Striatum to cerebellum SUVr steadily increased over time
but tended to level off after about 60 min post injection
(Fig. 1c). Therefore, for assessment of the size of the specific
signal, the interval 60–90 min post injection was used.
Baseline striatum to cerebellum SUVr were 1.56, 1.70,
and 1.22 and reduced to 0.97, 0.96, and 1.01 post-aprepitant,
Table 1. Pre- and post-aprepitant SUVr (60–90 min post injection), together with their ratio
Subject 1 Subject 2 Subject 3
Pre Post Pre/post Pre Post Pre/post Pre Post Pre/post
Striatum 1.56 0.97 1.61 1.70 0.96 1.77 1.22 1.01 1.21
Caudate 1.33 0.85 1.57 1.55 0.86 1.80 1.04 0.92 1.13
Putamen 1.95 1.19 1.64 1.95 1.16 1.69 1.61 1.19 1.35
Thalamus 1.14 0.98 1.16 1.30 1.12 1.16 0.83 1.02 0.81
Frontal Ctx 1.22 1.00 1.22 1.24 1.02 1.22 0.97 0.97 1.00
Cingulate 1.27 1.07 1.19 1.22 1.02 1.20 1.12 1.11 1.00
MTL 1.02 0.91 1.12 1.16 0.97 1.20 1.08 1.02 1.06
Insula 1.25 1.07 1.17 1.18 1.05 1.13 1.11 1.07 1.04
Parietal Ctx 1.24 1.00 1.24 1.24 0.99 1.24 0.93 0.99 0.95
Occipital Ctx 1.29 1.06 1.22 1.29 1.01 1.27 1.14 1.08 1.05
Ctx cortex, MTL medial temporal lobe
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respectively. Pre- and post-aprepitant SUVr for all ROIs are
shown in Table 1, together with their ratio. Note that, in
subject number 3, the latter ratio is smaller than 1 for parietal
cortex and thalamus, which is probably within measurement
error, at least for parietal cortex, although a small movement
artifact for thalamus cannot be excluded. More importantly,
pre- to post-aprepitant ratios of SUVr ranged from 1.21 to
1.77 for striatum (Table 1).
Discussion
This is the first study using the highly selective novel PET
ligand [11C]R116301 in human subjects. The distribution of
this tracer corresponds to the known distribution of NK1
receptors, with high retention in striatum (caudate and
putamen) and much lower retention in cortical areas [5].
Blocking studies with the NK1 antagonist aprepitant caused
a substantial reduction of the specific signal of [11C]
R116301 to background levels, confirming selectivity of
binding to the NK1 receptor. On the other hand, the rather
low target to cerebellum SUVr suggests a relatively high
degree of nonspecific binding in humans.
The signal in the cerebellum could not be blocked by
aprepitant, confirming that the density of NK1 receptors in
human cerebellum is negligible [5]. Consequently, cerebel-
lum can be used as reference region, i.e., as an estimate of free
and nonspecific binding. Therefore, for the blocking studies,
the ratio of target to cerebellum SUVr relative to baseline was
used as outcome measure. The size of the specific signal was
assessed at the interval 60–90 min post injection, as SUVr
seemed to become fairly constant within this time span.
It should be noted that striatum to cerebellum SUVr for the
baseline scan of subject 3 was lower than that of the other two
subjects, indicating lower specific binding (Fig. 1c). Subject 3
was, however, screened in the same manner as the other two
subjects, and all parameters were within normal range.
Although a moderate age effect (7% decrease per decade,
significant in other regions than striatum) on NK1 receptor
density has been reported [34], both age and gender could not
explain this lower binding, as subject 3 was a man of 42 years.
With the present sample size, it is not possible to assess
whether the observed intersubject variability was due to
biology (e.g., polymorphism with modulating effects on
affinity of the receptor) or methodology (i.e., effect of using
a simple SUVr for quantification). Further studies are needed
to address these issues, in particular assessing the validity of
using SUVr as outcome measure. In addition, a tracer kinetic
model for more quantitative analyses of [11C]R116301 data
needs to be developed.
At present, [18F]SPARQ is a PET tracer that provides a
much higher specific signal than [11C]R116301. Therefore, at
least in theory, it should provide a more accurate assessment
of NK1 receptor status or occupancy. Nevertheless, for
clinical applications, [18F]SPARQ is far from ideal because
of its slow kinetics, requiring very long study durations,
thereby increasing the risk of movement artifacts. At the cost
of a reduced signal, [11C]R116301 has the advantage that
studies can be performed within a reasonable time (90 min).
When ranking the affinity of various NK1 ligands based
on pKi values versus [
3H]SP (substance P), the following or-
der (from high to low) is obtained: GR205171 9 aprepitant 9
R116301 9 substance P [35]. It is likely that the affinity of
SPARQ [5] is higher or equal than that of GR205171. It is
clear that the affinity of R116301 is lower than that of
SPARQ, which is in agreement with the higher specific signal
observed with [18F]SPARQ. On the other hand, the lower
affinity of R116301 implies that [11C]R116301 could be more
sensitive to differences in endogenous substance P concen-
trations. This would be very interesting in intervention
studies, where release of the endogenous ligand could be
manipulated by a pharmacological challenge or, for example,
a fear stimulus. Clearly, further studies are needed to establish
whether this is feasible.
The NK1 receptor has shown to be an enigmatic target for
neuroscience drug discovery and development. To date,
antagonists for the NK1 receptor have shown efficacy in the
prevention of chemotherapy-induced nausea and vomiting.
Although both NK1 receptors and substance P are widely
distributed in the brain and may be involved in many
neuropsychiatric disorders, many clinical trials on anxiety
and depression have found no therapeutic effects of antago-
nist drugs. Nevertheless, Casopitant® (GlaxoSmith Kline), an
NK1 antagonist, is still under clinical investigation for a
variety of disorders, including phase II studies in anxiety and
depression. Availability of a PET tracer could facilitate
further clinical exploration of NK1 receptor involvement in
a variety of neuropsychiatric disorders and serve as a tool for
the development of drugs that target the NK1 receptor. The
present study demonstrates that [11C]R116301 could be a
potential candidate tracer for those investigations.
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